IPP Bureau
Glenmark launches AKYNZEO I.V. in India
By IPP Bureau - January 24, 2023
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
Marksans Pharma announces UK MHRA approval for Fluoxetine 20mg/5ml Oral Solution
By IPP Bureau - January 24, 2023
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) Ltd. located at Gifford House, Slaidburn Crescent, Southport, UK
Syngene Q3FY23 revenue reaches Rs. 803 Cr; PAT reaches Rs. 110 Cr
By IPP Bureau - January 24, 2023
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Gland Pharma’s Q3 FY23 revenue stood at Rs. 938 Cr with gross margin of 54%
By IPP Bureau - January 24, 2023
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Supriya Lifescience appoints Krishna Raghunathan as CFO
By IPP Bureau - January 24, 2023
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Astellas announces hold lifted by FDA on Fortis clinical trial of AT845
By IPP Bureau - January 23, 2023
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
SK bioscience appoints new executives
By IPP Bureau - January 23, 2023
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
By IPP Bureau - January 23, 2023
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Moderna announces an investigational respiratory syncytial vaccine mRNA-1345
By IPP Bureau - January 23, 2023
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Pfizer expands ‘An Accord for a Healthier World’ product offering in 45 lower-income countries
By IPP Bureau - January 23, 2023
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
G20: Medical Value Travel is an essential component for idealistic healthcare to address disparities of healthcare systems: Kotecha
By IPP Bureau - January 21, 2023
Multilateral collaborations will serve to strengthen knowledge sharing to formulate framework for accessible, affordable, and quality healthcare
Marksans Pharma raises Rs. 372.40 crores
By IPP Bureau - January 21, 2023
OrbiMed's exercise of warrant conversion will further strengthen the company's net cash position to over Rs.650 crores.
Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe
By IPP Bureau - January 21, 2023
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Briefs: Bafna Pharmaceuticals, Strides Pharma, IOL Chemicals and Pharmaceuticals and Krsnaa Diagnostics
By IPP Bureau - January 21, 2023
The National Institute of Pharmacy and Nutrition, Hungary has issued 'Certificate of GMP Compliance of Manufacturer' for IOL Chemicals and Pharmaceuticals Limited's products.
G 20: Medical Value Travel could be focused on maintaining, improving or restoring health through medical intervention: Dr V K Paul
By IPP Bureau - January 21, 2023
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
